HSulf-2 promotes basement membrane proteolysis via up-regulation of MMP-9 activity and promotes progression of DCIS to IDC thus opening avenues to therapeutically target HSulf-2. This evidence concerns the gene MMP9 and ductal breast carcinoma in situ.